120 related articles for article (PubMed ID: 11504802)
1. GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys.
Butelman ER; Ko MC; Traynor JR; Vivian JA; Kreek MJ; Woods JH
J Pharmacol Exp Ther; 2001 Sep; 298(3):1049-59. PubMed ID: 11504802
[TBL] [Abstract][Full Text] [Related]
2. kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception.
Butelman ER; Ko MC; Sobczyk-Kojiro K; Mosberg HI; Van Bemmel B; Zernig G; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):595-601. PubMed ID: 9580603
[TBL] [Abstract][Full Text] [Related]
3. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
4. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
5. Systemic effects of E-2078, a stabilized dynorphin A(1-8) analog, in rhesus monkeys.
Butelman ER; Vivian JA; Yu J; Kreek MJ; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(2):190-6. PubMed ID: 10326782
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys.
Butelman ER; Ball JW; Kreek MJ
Psychopharmacology (Berl); 2002 Oct; 164(1):115-20. PubMed ID: 12373425
[TBL] [Abstract][Full Text] [Related]
7. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys.
Butelman ER; Negus SS; Ai Y; de Costa BR; Woods JH
J Pharmacol Exp Ther; 1993 Dec; 267(3):1269-76. PubMed ID: 8263790
[TBL] [Abstract][Full Text] [Related]
8. kappa-Opioid receptor effects of butorphanol in rhesus monkeys.
Vivian JA; DeYoung MB; Sumpter TL; Traynor JR; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Jul; 290(1):259-65. PubMed ID: 10381785
[TBL] [Abstract][Full Text] [Related]
9. Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys.
Butelman ER; Ball JW; Kreek MJ
Psychoneuroendocrinology; 2004 Apr; 29(3):307-26. PubMed ID: 14644063
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
Ko MC; Butelman ER; Traynor JR; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):518-26. PubMed ID: 9580592
[TBL] [Abstract][Full Text] [Related]
11. Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
Heyliger SO; Jackson C; Rice KC; Rothman RB
Synapse; 1999 Dec; 34(4):256-65. PubMed ID: 10529720
[TBL] [Abstract][Full Text] [Related]
12. Differential antagonism of the rate-decreasing effects of kappa-opioid receptor agonists by naltrexone and norbinaltorphimine.
Powell KR; Holtzman SG
Eur J Pharmacol; 1999 Jul; 377(1):21-8. PubMed ID: 10448921
[TBL] [Abstract][Full Text] [Related]
13. Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-opioid receptors.
Patkar KA; Wu J; Ganno ML; Singh HD; Ross NC; Rasakham K; Toll L; McLaughlin JP
J Pharmacol Exp Ther; 2013 Sep; 346(3):545-54. PubMed ID: 23853171
[TBL] [Abstract][Full Text] [Related]
14. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
Negus SS; Schrode K; Stevenson GW
Exp Clin Psychopharmacol; 2008 Oct; 16(5):386-99. PubMed ID: 18837635
[TBL] [Abstract][Full Text] [Related]
15. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.
Rothman RB; France CP; Bykov V; De Costa BR; Jacobson AE; Woods JH; Rice KC
Eur J Pharmacol; 1989 Aug; 167(3):345-53. PubMed ID: 2553442
[TBL] [Abstract][Full Text] [Related]
17. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.
Ko MC; Johnson MD; Butelman ER; Willmont KJ; Mosberg HI; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1113-20. PubMed ID: 10565831
[TBL] [Abstract][Full Text] [Related]
18. Ligand binding profiles of U-69, 593-sensitive and-insensitive sites in human cerebral cortex membranes: evidence of kappa opioid receptors heterogeneity.
Kim KW; Eun YA; Soh SM; Eun JS; Cho KP
Life Sci; 1996; 58(19):1671-9. PubMed ID: 8632704
[TBL] [Abstract][Full Text] [Related]
19. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.
Remmers AE; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1999 Feb; 288(2):827-33. PubMed ID: 9918595
[TBL] [Abstract][Full Text] [Related]
20. GR89,696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus.
Caudle RM; Mannes AJ; Iadarola MJ
J Pharmacol Exp Ther; 1997 Dec; 283(3):1342-9. PubMed ID: 9400009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
